RayKnowChina Research Map
Shortlist

RecruitingBreast cancerPhase 3

Registered title, quoted from ClinicalTrials.gov

JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects

An open trial on breast cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 60 hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 60

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteAffiliated Cancer Hospital of Xinjiang Medical University新疆医科大学附属肿瘤医院UrumqiHospital page
  2. Study siteAffiliated Hospital of Guangdong Medical University广东医科大学附属医院ZhanjiangHospital page
  3. Study siteAffiliated Hospital of Guizhou Medical University贵州医科大学附属医院GuiyangHospital page
  4. Study siteAffiliated Hospital of Hebei University河北大学附属医院ShijiazhuangHospital page
  5. Study siteAffiliated Hospital of Qingdao University青岛大学附属医院QingdaoHospital page
  6. Study siteAffiliated Hospital of Qinghai University青海大学附属医院XiningHospital page
  7. Study siteAffiliated Hospital of Xuzhou Medical University徐州医科大学附属医院XuzhouHospital page
  8. Study siteAffiliated Hospital of Zunyi Medical University遵义医学院附属医院ZunyiHospital page
  9. Study siteAnyang Tumor Hospital安阳市肿瘤医院AnyangHospital page
  10. Study siteFirst Affiliated Hospital of Anhui Medical University安徽医科大学第一附属医院HefeiHospital page
  11. Study siteFirst Affiliated Hospital of Chongqing Medical University重庆医科大学附属第一医院ChongqingHospital page
  12. Study siteFirst Affiliated Hospital of Henan University of Science and Technology河南科技大学第一附属医院LuoyangHospital page
  13. Study siteFirst Affiliated Hospital of USTC中国科学技术大学附属第一医院(安徽省立医院)HefeiHospital page
  14. Study siteFirst Affiliated Hospital of Xi'an Jiaotong University西安交通大学第一附属医院Xi'anHospital page
  15. Study siteFirst Affiliated Hospital of Xiamen University厦门大学附属第一医院XiamenHospital page
  16. Study siteFirst Affiliated Hospital of Xinxiang Medical University河南医药大学第一附属医院XinxiangHospital page
  17. Study siteFirst Affiliated Hospital of Zhengzhou University郑州大学第一附属医院ZhengzhouHospital page
  18. Study siteFirst Affiliated Hospital, University of South China南华大学附属第一医院HengyangHospital page
  19. Study siteFirst Affiliated Hospital, Zhejiang University浙江大学医学院附属第一医院HangzhouHospital page
  20. Study siteFirst Hospital of China Medical University中国医科大学附属第一医院ShenyangHospital page
  21. Study siteFirst Hospital of Jilin University吉林大学第一医院ChangchunHospital page
  22. Study siteFirst Hospital of Lanzhou University兰州大学第一医院LanzhouHospital page
  23. Study siteFudan University Shanghai Cancer Center复旦大学附属肿瘤医院ShanghaiHospital page
  24. Study siteFujian Cancer Hospital福建省肿瘤医院FuzhouHospital page
  25. Study siteFujian Medical University Union Hospital福建医科大学附属协和医院FuzhouHospital page
  26. Study siteFujian Provincial Hospital福建省立医院FuzhouHospital page
  27. Study siteGuangdong Provincial People's Hospital广东省人民医院GuangzhouHospital page
  28. Study siteGuizhou Provincial People's Hospital贵州省人民医院GuiyangHospital page
  29. Study siteHarbin Medical University Cancer Hospital哈尔滨医科大学附属肿瘤医院HarbinHospital page
  30. Study siteHenan Cancer Hospital河南省肿瘤医院ZhengzhouHospital page
  31. Study siteHunan Cancer Hospital湖南省肿瘤医院ChangshaHospital page
  32. Study siteJiangsu Cancer Hospital江苏省肿瘤医院NanjingHospital page
  33. Study siteJiangsu Provincial People's Hospital江苏省人民医院(南京医科大学第一附属医院)NanjingHospital page
  34. Study siteJiangxi Cancer Hospital江西省肿瘤医院NanchangHospital page
  35. Study siteLiaoning Cancer Hospital & Institute辽宁省肿瘤医院ShenyangHospital page
  36. Study siteLinyi Cancer Hospital临沂市肿瘤医院LinyiHospital page
  37. Study siteMeizhou People's Hospital梅州市人民医院MeizhouHospital page
  38. Study siteNational Cancer Center / Cancer Hospital, CAMS中国医学科学院肿瘤医院BeijingHospital page
  39. Study sitePeking University Cancer Hospital北京大学肿瘤医院BeijingHospital page
  40. Study siteSecond Affiliated Hospital of Anhui Medical University安徽医科大学第二附属医院HefeiHospital page
  41. Study siteSecond Affiliated Hospital of Soochow University苏州大学附属第二医院SuzhouHospital page
  42. Study siteSecond Affiliated Hospital of Xi'an Jiaotong University西安交通大学第二附属医院Xi'anHospital page
  43. Study siteSecond Affiliated Hospital, Zhejiang University浙江大学医学院附属第二医院HangzhouHospital page
  44. Study siteSecond Hospital of Dalian Medical University大连医科大学附属第二医院DalianHospital page
  45. Study siteShandong Cancer Hospital and Institute山东省肿瘤医院JinanHospital page
  46. Study siteShantou University Medical College hospitals汕头大学医学院附属医院ShantouHospital page
  47. Study siteShanxi Cancer Hospital山西省肿瘤医院TaiyuanHospital page
  48. Study siteSichuan Cancer Hospital四川省肿瘤医院ChengduHospital page
  49. Study siteSichuan Provincial People's Hospital四川省人民医院ChengduHospital page
  50. Study siteSun Yat-sen Memorial Hospital中山大学孙逸仙纪念医院GuangzhouHospital page
  51. Study siteSun Yat-sen University Cancer Center中山大学肿瘤防治中心GuangzhouHospital page
  52. Study siteTianjin Medical University Cancer Institute & Hospital天津医科大学肿瘤医院TianjinHospital page
  53. Study siteUnion Hospital华中科技大学同济医学院附属协和医院WuhanHospital page
  54. Study siteWest China Hospital四川大学华西医院ChengduHospital page
  55. Study siteXiangya Hospital中南大学湘雅医院ChangshaHospital page
  56. Study siteXiangyang Central Hospital襄阳市中心医院XiangyangHospital page
  57. Study siteXuzhou Central Hospital徐州市中心医院XuzhouHospital page
  58. Study siteYunnan Cancer Hospital云南省肿瘤医院KunmingHospital page
  59. Study siteZhejiang Cancer Hospital浙江省肿瘤医院HangzhouHospital page
  60. Study siteZhongnan Hospital of Wuhan University武汉大学中南医院WuhanHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06079983, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 6

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (6 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. Have received at least 1 to 2 lines of chemotherapy regimens for breast cancer in the relapse/metastatic stage.

    Inclusion criterion 4

  3. Previous use of antibody conjugates containing topoisomerase I inhibitors. 6. There is a third gap fluid that cannot be controlled by drainage, etc. 7. Previous or current interstitial pneumonia/lung disease requiring systemic hormone therapy.

    Exclusion criterion 4

  4. Expected survival ≥ 3 months. 9. ECOG score of 0 or 1 within 14 days prior to administration. 10. Female subjects of childbearing potential or male subjects of fertile partner consent to use highly effective contraception from the signing of informed consent.

    Inclusion criterion 8

  5. At least one extracranial measurable lesion at baseline according to RECIST 1.1 criteria.

    Inclusion criterion 7

  6. Patients with only skin lesions as target lesions. 3. Those with a history of other primary malignant tumors within 5 years before administration.

    Exclusion criterion 2

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; blood tests: counts, liver and kidney function; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06079983, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • 1. The subject is able to understand the informed consent form, voluntarily participate and sign the informed consent form.
  • The subject ≥ 18 years old on the day of signing the informed consent form, male or female.
  • Unresectable locally recurrent or metastatic breast cancer, previous histopathological reports of HER2 IHC 1+ or 2+ and ISH-, previous histopathological reports have not been diagnosed as HER2 IHC 3+ or 2+ and ISH+.
  • Have received at least 1 to 2 lines of chemotherapy regimens for breast cancer in the relapse/metastatic stage.
  • Willing to provide sufficient archived tumor pathology specimens for central laboratory detection of HER2 status.
  • Documented radiographic disease progression (during or after the most recent treatment).
  • At least one extracranial measurable lesion at baseline according to RECIST 1.1 criteria.
  • Expected survival ≥ 3 months. 9. ECOG score of 0 or 1 within 14 days prior to administration. 10. Female subjects of childbearing potential or male subjects of fertile partner consent to use highly effective contraception from the signing of informed consent.
  • Laboratory tests within 14 days before administration and cardiac function tests within 28 days meet the criteria.
  • Have sufficient elution of previous treatment before administration.

Exclusion Criteria:

  • 1. Untreated, or unstable brain parenchymal metastases, spinal cord metastases or compression, cancerous meningitis.
  • Patients with only skin lesions as target lesions. 3. Those with a history of other primary malignant tumors within 5 years before administration.
  • Selection of the control drug by the investigator who is not suitable for the protocol prescribed.
  • Previous use of antibody conjugates containing topoisomerase I inhibitors. 6. There is a third gap fluid that cannot be controlled by drainage, etc. 7. Previous or current interstitial pneumonia/lung disease requiring systemic hormone therapy.
  • Inability to swallow, chronic diarrhea, intestinal obstruction, or other factors that affect oral administration and absorption of the drug.
  • Previous or current autoimmune disease. 10. Have uncontrolled comorbidities. 11. The toxicity of previous antitumor therapy has not been restored to grade ≤1 (NCI-CTCAE v5.0).
  • History of previous immunodeficiency. 13. History of life-threatening allergic reactions or known ≥ grade 3 allergy to any component or excipient in the investigational pharmaceutical formulation.
  • Other conditions that the investigators believe will affect the safety or adherence to drug treatment in this study, including but not limited to psychiatric disorders, alcohol or drug abuse.

Quoted from ClinicalTrials.gov, NCT06079983, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06079983, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06079983